TDMS Study 88122-07 Pathology Tables
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
final#1/Mice
Facility: Battelle Columbus Laboratory
Chemical CAS #: 37319-17-8
Lock Date: 04/14/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 8 6 10 9
Moribund Sacrifice 4 5 3 7
Accidently Killed 1
Dosing Accident 1
Survivors
Terminal Sacrifice 37 37 37 34
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (39) (40) (38) (38)
Sarcoma, Metastatic, Uterus 1 (3%)
Intestine Large, Cecum (41) (43) (44) (43)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (41) (44) (42) (42)
Polyp Adenomatous 2 (5%) 1 (2%)
Intestine Small, Jejunum (43) (44) (42) (42)
Carcinoma 1 (2%)
Intestine Small, Ileum (42) (44) (42) (42)
Liver (50) (49) (50) (49)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) 4 (8%)
Hepatocellular Carcinoma 3 (6%) 3 (6%) 5 (10%) 3 (6%)
Hepatocellular Adenoma 6 (12%) 3 (6%) 2 (4%) 9 (18%)
Hepatocellular Adenoma, Multiple 1 (2%) 2 (4%) 2 (4%) 6 (12%)
Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 2 (4%)
Sarcoma, Metastatic, Uterus 1 (2%)
Mesentery (30) (34) (32) (42)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (3%) 1 (2%)
Sarcoma 1 (3%)
Sarcoma, Metastatic, Skin 1 (3%) 2 (6%) 2 (6%) 1 (2%)
Sarcoma, Metastatic, Uterus 1 (3%) 1 (3%)
Pancreas (46) (45) (46) (46)
Page 2
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (49) (49) (50) (48)
Stomach, Forestomach (47) (48) (49) (48)
Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Glandular (46) (45) (44) (46)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Pericardium, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (49) (48)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Subcapsular, Carcinoma 1 (2%)
Adrenal Medulla (49) (49) (47) (47)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (48) (47) (45) (48)
Pars Distalis, Adenoma 2 (4%) 3 (6%) 4 (9%) 2 (4%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Sarcoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (47) (46) (47) (48)
Cystadenoma 1 (2%) 1 (2%) 2 (4%)
Hemangioma 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 1 (2%)
Page 3
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Sarcoma, Metastatic, Mesentery 1 (2%)
Uterus (48) (49) (50) (50)
Histiocytic Sarcoma 2 (4%)
Polyp Stromal 3 (6%) 1 (2%) 2 (4%) 2 (4%)
Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (48) (50) (49)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (6%)
Lymph Node (6) (10) (5) (10)
Bronchial, Histiocytic Sarcoma 2 (20%)
Bronchial, Osteosarcoma, Metastatic,
Uncertain Primary Site 1 (20%)
Lumbar, Histiocytic Sarcoma 1 (10%)
Mediastinal, Histiocytic Sarcoma 2 (20%)
Mediastinal, Osteosarcoma, Metastatic,
Uncertain Primary Site 1 (20%)
Mediastinal, Sarcoma, Metastatic, Skin 1 (17%)
Pancreatic, Sarcoma, Metastatic, Skin 1 (17%)
Renal, Sarcoma, Metastatic, Skin 1 (10%)
Lymph Node, Mandibular (33) (38) (37) (39)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (47) (44) (42) (45)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Spleen (47) (48) (47) (46)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Thymus (43) (38) (43) (36)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma, Metastatic, Skin 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Basal Cell Adenoma 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Page 4
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
Subcutaneous Tissue, Myxoma 1 (2%)
Subcutaneous Tissue, Sarcoma 3 (6%) 4 (8%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (2) (2)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (50%)
Sarcoma, Metastatic, Uterus 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Histiocytic Sarcoma 2 (4%)
Meningioma Malignant 1 (2%)
Oligodendroglioma Benign 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (4%) 2 (4%)
Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%)
Liposarcoma, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 3 (6%) 2 (4%) 1 (2%)
Mediastinum, Osteosarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Page 5
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Nose (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Pleura (1)
Sarcoma, Metastatic, Lung 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (48) (41) (50) (46)
Adenoma 3 (6%) 3 (7%) 4 (8%) 3 (7%)
Carcinoma 2 (5%) 2 (4%) 2 (4%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (49) (48) (46)
Histiocytic Sarcoma 4 (8%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (43) (46) (47) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 4 (8%) 1 (2%) 3 (6%)
Lymphoma Malignant 7 (14%) 8 (16%) 6 (12%) 16 (32%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 29 34 29 40
Total Primary Neoplasms 39 50 41 64
Total Animals with Benign Neoplasms 17 16 14 26
Total Benign Neoplasms 21 20 19 30
Total Animals with Malignant Neoplasms 17 22 19 28
Total Malignant Neoplasms 18 30 22 34
Total Animals with Metastatic Neoplasms 4 5 7 6
Total Metastatic Neoplasm 7 13 24 9
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 4 5 8 15
Moribund Sacrifice 7 4 4 3
Dosing Accident 1 2
Survivors
Terminal Sacrifice 39 40 38 30
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (47) (47) (42)
Sarcoma, Metastatic, Liver 1 (2%)
Intestine Large, Cecum (49) (47) (46) (39)
Carcinoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Intestine Small, Duodenum (47) (47) (44) (40)
Carcinoma 1 (2%)
Polyp Adenomatous 1 (3%)
Intestine Small, Jejunum (47) (47) (44) (38)
Carcinoma 4 (9%) 1 (2%)
Polyp Adenomatous 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Liver (50) (50) (50) (50)
Hemangiosarcoma 2 (4%) 4 (8%) 9 (18%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 7 (14%) 12 (24%) 11 (22%) 11 (22%)
Hepatocellular Carcinoma, Multiple 4 (8%) 1 (2%) 4 (8%) 2 (4%)
Hepatocellular Adenoma 10 (20%) 12 (24%) 10 (20%) 10 (20%)
Hepatocellular Adenoma, Multiple 9 (18%) 3 (6%) 5 (10%) 10 (20%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (10) (4) (20) (10)
Sarcoma 1 (5%)
Pancreas (50) (50) (49) (50)
Page 8
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Stomach, Forestomach (49) (50) (50) (50)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (49) (49) (48) (46)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (49)
Adenoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Subcapsular, Adenoma 2 (4%)
Adrenal Medulla (50) (50) (50) (49)
Pheochromocytoma Benign 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 2 (4%)
Pituitary Gland (47) (48) (49) (48)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (48) (49) (50) (49)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Preputial Gland (49) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Seminal Vesicle (50) (50) (50) (49)
Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Testes (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma 1 (2%)
Lymph Node (1) (1) (1) (1)
Mediastinal, Mast Cell Tumor Malignant,
Metastatic, Bone Marrow 1 (100%)
Lymph Node, Mandibular (28) (29) (30) (30)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (3%)
Lymph Node, Mesenteric (48) (46) (45) (41)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Spleen (49) (50) (49) (49)
Hemangiosarcoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Page 10
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Marrow 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50) (50)
Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Melanoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Chondroma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Skeletal Muscle (2) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (50%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 9 (18%) 3 (6%) 8 (16%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 3 (6%) 5 (10%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 3 (6%) 10 (20%) 5 (10%)
Histiocytic Sarcoma 1 (2%)
Page 11
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Mediastinum, Mast Cell Tumor Malignant,
Metastatic, Bone Marrow 1 (2%)
Nose (50) (50) (50) (47)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Pleura (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (49) (48) (49) (48)
Adenoma 6 (12%) 9 (19%) 4 (8%) 6 (13%)
Carcinoma 1 (2%) 2 (4%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Urinary Bladder (50) (49) (49) (49)
Hemangiosarcoma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 3 (6%)
Lymphoma Malignant 3 (6%) 1 (2%) 2 (4%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 88122-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ELMIRON Date: 04/23/01
Route: GAVAGE Time: 15:05:34
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 56 MG/KG 168 504
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 32 41 42
Total Primary Neoplasms 69 52 71 75
Total Animals with Benign Neoplasms 29 24 29 27
Total Benign Neoplasms 38 29 36 34
Total Animals with Malignant Neoplasms 24 20 27 30
Total Malignant Neoplasms 31 23 35 41
Total Animals with Metastatic Neoplasms 8 5 11 6
Total Metastatic Neoplasm 12 25 12 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------